(Total Views: 273)
Posted On: 06/13/2022 11:01:39 PM
Post# of 1418
Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia - 13 Jun, 2022, 19:32 IST
https://www.prnewswire.com/in/news-releases/d...96936.html
"In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19)."
What? 36 people? Are you kidding me?
The message board 'experts' said companies have 1000's in these types of trials and they take 3 years.
https://www.prnewswire.com/in/news-releases/d...96936.html
"In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19)."
What? 36 people? Are you kidding me?
The message board 'experts' said companies have 1000's in these types of trials and they take 3 years.
(2)
(0)
